Conference report: Nivolumab plus ipilimumab with two cycles of chemotherapy demonstrates durable overall survival vs. chemotherapy at two years as first-line treatment of non-small cell lung cancer in phase III CheckMate -9LA trial

In trial, 38% on combination regimen with 2 cycles of chemotherapy were alive at 2 years vs. 26% on chemotherapy alone. With additional follow-up, median overall survival (primary endpoint) was 15.8 months vs. 11.0 months, respectively (HR 0.72; 95% CI 0.61-0.86).

Source:

Biospace Inc.